09/11/2020
Philogen will be attending the PEGS Europe Virtual Conference from November 9 to 12, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Presentation in the Tumor Microenvironment Session (Immunotherapy Stream) on November 10 with the title: Immunocytokines with "Activity on Demand".
Prof. Dario Neri will also give a Lecture in the Antibody-Drug Conjugates Session (Oncology Stream) on November 10 with the title: Antibody-Drug Conjugates (ADCs) and Small-Molecule Drug Conjugates (SMDCs): A Comparative Analysis.
02/11/2020
Philogen will be attending the Next Generation Protein Therapeutics & Bioconjugates Summit from November 2 to 5, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Lecture with the title: Cancer Therapy Using Antibody-Cytokine Fusion Proteins.
08/10/2020
Philogen announces publication of malignant brain tumor study results in Science Translational Medicine.
Press Release
15/09/2020
Philogen will be attending the World ADC Digital Conference from September 15 to 18, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Plenary Lecture on: “Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation”.
20/08/2020
Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich web site. Read the full story here.
Always ask the important questions
17/07/2020
Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients”
Link to Paper
26/06/2020
Philogen received clinical trial authorisation with NIDLEGYTM in nonmelanoma skin cancer
NIDLEGY authorisation in nonmelanoma skin cancer24/06/2020
PR Nidlegy Combination Pack Approval
Philogen received combination pack approval for NidlegyTM
28/04/2020
Philogen announces Option Exercise by Janssen
PR Option Exercise by JANSSEN